Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-327

Hi All,

Another antagonist looking to take advantage of current shananagans.

In the most recent ASX announcement 10 March 2020 – please pay attention to the following:

Intellectual Property

Mesoblast’s intellectual property (IP) portfolio encompasses over 1,000 patents or patent applications in all major markets and includes the use of MSCs obtained from any source for patients with acute respiratory distress syndrome (ARDS), and for inflammatory lung disease due to coronavirus (COVID-19), influenza and other viruses. Additionally, these patents cover Mesoblast’s manufacturing processes that yield industrial-scale cellular medicines. This IP position is expected to provide Mesoblast with substantial commercial advantages as it develops its product candidates for these conditions.

My opinion

The above (in code) is a shot across the bow for anyone and everyone who wants to develop a commercial offering in MSC’s (research is ok ..but patents kick in on any commercialization) . I wanted to check my thinking with a respected friend of mine (specialist) and my thinking is confirmed.

Please take the time to read the para again – and pay specific attention to the references made to “source” and “manufacturing”.

IMO – the value of ourPatents is on level pegging with our Technology.

JCR / Takeda / Grunenthal / M&G are prove of this fact.

Upcoming mile stones

Focus on:

(1) Upcoming Ryonsil timeline and results.

(2) Upcoming CHF and CLBP results

(3) At the same time.. we await updates on COVID-19 and MSB initiatives

YoungandNaïve – please share this post on disallowed

GLTAH.